Guys. This is P.1. It isn’t “new” or “novel.” It has now been detected in cases in the U.K. We know the vaccines can neutralize this variant, and updated boosters should they be needed are already in development. Please don’t be alarmed. This is what viruses do, they spread.
Keep in mind this study only takes into account humoral immunity and nAbs rather than cell mediated immunity as well (which I am a huge advocate for) but you can see the vaccines can neutralize P.1. medrxiv.org/content/10.110…
I wanted to clarify since some have been misconstruing my words. If you are confused, it’s better to ask me rather than not. I have never said P.1 was not a VOC. In fact, if you look through several of my threads I have highlighted and said otherwise. What I am trying to express
is that this variant has been present since last year when it appeared it Brazil, then Japan and now parts of the UK and EU. Several outlets weren’t even specifying this was P.1. I have also said, yes, the vaccines are effective and will prevent you from facing severe disease.
I am always open for discussion and helping people understand when they are confused or concerned.
Thank you Professor for giving insight as to when this variant did emerge. Initially I was looking at reports of December of last year.
And please see here for more clarification. The November estimate some have been seeing corresponds to the arrival and spread of the variant in Manaus, Brazil, not taking into account other areas such as Rio de Janeiro where it was widespread earlier.
While it is speculative due to lack of sequencing at the time we can see when AZN’s vaccine were used during Phase III trials. Will we need more data? Absolutely. What I try to express is that the vaccines are effective even with decreased neutralization. ox.ac.uk/news/2020-06-2…
For Pfizer’s and Moderna’s vaccines, they have shown effectiveness against these variants based on nAbs alone. Again, what I want everyone to understand is this variant is not new or novel. It’s been here for a while now.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The importance of T-cell immunity! This study finds CD4+ and CD8+ T-cell mediated responses are minimally affected by mutations found in SARS-CoV-2 VOCs (B.1.1.7, B.1.351, & P.1.) and VOI CAL20.C! Immunity is about more than just antibodies! Let’s go! 🧵 biorxiv.org/content/10.110…
Researchers utilized convalescent plasma to directly assess TCRs from persons recovered from previous SARS-CoV-2 infections obtained before the emergence of the variants, and from recent Moderna and Pfizer vaccine recipients for their capacity to recognize peptides derived from
the ancestral reference sequence as well as the B.1.1.7, B1.351, P.1 and the CAL.20C variants. Bioinformatic analyses were utilized to predict the impact of mutations in the various variants with sets of previously reported CD4+ and CD8+ T cell epitopes derived from the ancestral
Some good news for your day! The latest real-world study from Public Health England (PHE) shows that both Pfizer’s AND Oxford-AstraZeneca’s vaccines are both highly effective in reducing SARS-CoV-2 infections among older people aged 70 years and over. khub.net/documents/1359…
Since January, protection against symptomatic COVID, 4 weeks after the first dose, ranged between 57 and 61% for one dose of Pfizer’s vaccine and between 60 and 73% for Oxford-AstraZeneca’s vaccine. Their data shows symptomatic infections in those over 70 decreasing from around 3
weeks after one dose of either vaccine. In those over 80, study data suggested a single dose of either vaccine is more than 80% effective at preventing hospitalization, around 3 to 4 weeks post immunization. Evidence also suggests Pfizer’s vaccine, leads to an 83% reduction in
Ready for some wonderful news? Here we go! A recent study has found that a single dose of Pfizer’s vaccine can reduce the number of asymptomatic SARS-CoV-2 infections by 75%. This demonstrates these vaccines can greatly reduce the risk of transmission. 🧵 authorea.com/users/332778/a…
Cambridge University Hospitals NHS Foundation Trust and researchers at the University of Cambridge analyzed their results from thousands of COVID-19 tests carried out each week as part of their screening program on asymptomatic HCWs who showed no signs of infection.
Their vaccination program for HCWs began on December 8th of last year, with mass vaccination efforts continuing til January 8th of this year. During a two-week period between the 18th and 31st of January, researchers screened similar numbers of vaccinated and unvaccinated staff.
In relevance to the scaremongering going around right now concerning the New York variant B.1.526, let me save you all from having to click and scroll down the article.
This variant has not been shown yet to possess any evidence of functional significance or biological properties that make it a cause for concern to date. Please be aware.
Also for those getting upset at me saying people have a right to know about it, yeah you’re right. I absolutely agree. What do you think I’m doing? They also have a right to know what’s past your clickbait headlines and why they don’t need to be thrown into a panic.
Some good news for your evening! Now that it’s finally out I can share! Our updated mRNA-1273.351 Moderna vaccine is on its way to NIH to be tested in early stage clinical trials to determine if it can be used as a booster shot against variant B.1.351 (South Africa strain)!
Just so you guys have an idea on the approaches to boosting we are evaluating (also note that while YES, our vaccines do provide neutralizing activity against VOCs we are choosing to do these studies out of an abundance of caution and stay ahead):
The FDA Vaccines and Related Biological Products Advisory Committee briefing document on Johnson & Johnson’s COVID vaccine has been posted and their efficacy data looks extremely promising. It appears to elicit robust efficacy against all variants including B.1.351!
It also demonstrates its ability to elicit strong cell-mediated immunity via T-cell responses with protection rising over time. This is the first one-dose vaccine that could do a lot of wonders right now. EUA is expected this week.
Document is here: fda.gov/advisory-commi…
The efficacy of the Johnson & Johnson vaccine against moderate to severe/critical COVID-19 across all geographic areas was 66.9% at least 14 days after the single dose vaccination and 66.1% at least 28 days after vaccination. In addition, there were no specific safety concerns